Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218840

SCHEMBL23218840

SCHEMBL23218840

COC(=O)c1c(C(C)(C)C)oc2ccc(Br)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ HPGD P15428 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ HTT P42858 2/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ CYP2D6 P10635 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ GPR55 Q9Y2T6 1/20 0.57
▸ TSHR P16473 5/20 0.51
▸ MAPT P10636 4/20 0.51
▸ KDM4E B2RXH2 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ CA12 O43570 3/20 0.47
▸ CA9 Q16790 3/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ TP53 P04637 2/20 0.43
▸ NR4A2 P43354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853045 0.81 GAA (0.55) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL15020039 0.81 GAA (0.55) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL29852438 0.78 SLC22A12 (0.53) MEN1ALDH1A1HPGDKMT2ACYP1A2
SCHEMBL23218476 0.78 SLC22A12 (0.53) MEN1ALDH1A1HPGDKMT2ACYP1A2
SCHEMBL29853044 0.76 MAPT (0.49) MEN1ALDH1A1HPGDKMT2AHTT
SCHEMBL23218696 0.76 MAPT (0.49) MEN1ALDH1A1HPGDKMT2AHTT
SCHEMBL8709574 0.75 ALDH1A1 (0.53) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL2761737 0.75 CA12 (0.72) MEN1ALDH1A1HPGDKMT2AHTT
SCHEMBL23218333 0.75 TSHR (0.48) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A
SCHEMBL29853212 0.75 TSHR (0.48) SMN1; SMN2MEN1ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB SMN1; SMN2 3739/4885MEN1 1819/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB SMN1; SMN2 3669/4885MEN1 548/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.